Cardiovascular outcomes: the SELECT major-adverse-event result, SOUL, SUSTAIN 6 and REWIND, how to convert a hazard ratio into an absolute risk reduction, and whether the benefit is weight-mediated.
The clinician who ordered the panel was not concerned; I would still like to understand it. Please show the division. I want to check my own against yours. I would…
Stated plainly: SURPASS-3 · a GLP-1 receptor agonist. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…
Concretely: FLOW · semaglutide. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree, which…
What I have: SOUL · oral semaglutide. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics…
What I am working with: ESSENCE · semaglutide. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single…
I have three data points across nine months, which I hope is enough to see a trend. I would like the arithmetic checked rather than the conclusion asserted. I have…
Down 18% of body weight over ten months. My triglycerides have collapsed from 3.1 to 1.1 mmol/L, which is the change everyone predicted. My LDL-C has gone from 3.4 to…
My laboratory results are from the same laboratory each time, drawn fasting, which I gather matters. Please show the division. I want to check my own against yours. I…
My laboratory results are from the same laboratory each time, drawn fasting, which I gather matters. I want the working, not the result — I need to be able to redo it…
I keep seeing SELECT summarised as "semaglutide cuts heart attacks and strokes by 20%". I understand that 20% comes from the hazard ratio of 0.80, and I understand…
I have three data points across nine months, which I hope is enough to see a trend. I have the document in front of me and I can read the numbers. What I cannot do is…
The clinician who ordered the panel was not concerned; I would still like to understand it. The units are where I keep going wrong, so please be explicit about them.…
Setup, so nobody has to ask: SURMOUNT-1 · tirzepatide. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…
I have three data points across nine months, which I hope is enough to see a trend. I can do the algebra. I am not confident about the conversion factors. If there is…
This is a question about interpretation, not about whether to act — I will take action questions elsewhere. I want the working, not the result — I need to be able to…
The case in front of me: REDEFINE-1 · cagrilintide. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the…
I am reading the trial table rather than the press release, which is why the numbers differ. I want to understand what this actually establishes, as opposed to what…
Details up front: ATTAIN-1 · orforglipron. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…
I have the full paper rather than the abstract, and the supplementary appendix. I would rather understand the derivation than memorise the outcome. Two people I asked…
Stated plainly: TRIUMPH-3 · retatrutide. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I…
I have the full paper rather than the abstract, and the supplementary appendix. I can do the algebra. I am not confident about the conversion factors. If there is a…
The particulars: SUSTAIN-6 · semaglutide. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is that I am…
What I am working with: SELECT · semaglutide. I would like help reading this properly rather than being told what conclusion to reach. I have the full report…
Numbers first: SURMOUNT-4 · tirzepatide. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL Biochem